The company’s original mission was to develop a mild silver protein suspension that would remain stable at small particle size (17.6 nanometer) and effectively kill a variety of viruses, bacteria and fungi in the human body. We achieved this undertaking in mid-1990 and introduced our proprietary formulation to market under the Silver 400 brand name.

As technologies evolve, so have our formulation and product lines. Incorporating applied quantum physics technology has resulted in our researchers changing the composite matrix of the suspension base for all of our products. Each product formulation base presently utilizes three types of orthomolecular restructured water since 2000.

Importance of collaborative efforts-
Observations noted during early product testing, including comments and data furnished from participating healthcare researchers and practitioners have resulted in development of practicable guidelines for prescribing therapy protocol using our products to effectively treat a variety of conditions. MSP researcher’s recognized early on that its mild silver protein formulation could be targeted for use in IV infusion form to effectively treat serious illness. Results of collaborative data clearly indicated the astounding effectiveness of killing pathogens harmful to deep tissue . Conclusive test results from these early clinical studies laid the groundwork for developing the IV Infusion Protocol used by practitioners today.

Further observations noted during subsequent testing and evaluation of clinical data suggested that a person should “phase-in” treatments by taking Silver 400 orally in conjunction with major diet changes for at least thirty days before attempting an IV infusion. We confirmed our hypothesis from our findings and conclusions drawn from an additional study that revealed that over 80% of the American population have moderate to severe Candida Yeast overgrowth. Noted potential adverse reactions- Candida Yeast overgrowth condition when killed-off quickly resulted in varying degrees of headaches and nausea, which may last up to a few hours until the Candida is brought under control. Conclusion- Silver 400 is a highly efficient form of mild silver protein. It’s small particle size stabilized in our proprietary molecularly restructured base allows the protein bound 17.6 nanometer size silver particles to effectively enter deep tissue- especially, the lungs, kidneys, heart, and liver where most of the harmful pathogens reside, target and kill them. To minimize this effect, we suggest that a person should start with very low oral doses of Silver 400 to avoid massive die-off of Candida.

Protocol Implementation: Underlying problem Healthcare Practitioners face-
Unfortunately, today’s proliferation of new harmful pathogens limits protocol implementation. In many cases practitioners have noted that a person does not have thirty days to alter their diet and get the pathogens under control. The SARS virus has been shown to kill individuals in two to four days after symptoms appear. West Nile Virus has caused brain swelling in as little as eight hours after symptoms first appear. In these and other life threatening situations, we recommend that the affected person or a family member consult with a qualified healthcare professional to ascertain whether the patient should start IV infusions directly or consume higher doses of Silver 400 in an attempt to kill the virus(s) and other pathogens that have invaded the body.

“Silver 400” mild silver protein in todays practice-
MSP Research has developed the only mild silver protein product that can be used for IV infusions, taken orally, or applied topically. We have the ability to manufacture stable higher concentrations (PPM) where requested for specific therapy protocols. Today, our proprietary formulation is manufactured and sold worldwide directly by MSP Research and under private label by seven very large Nutraceutical B2B and B2C companies. Within the past few years over five thousand health practitioners worldwide have gained a distinct new perspective for Ag therapy protocols and the role our products can contribute in effectively treating their patients for a variety of conditions.

Your patient’s health is our concern-
We strongly feel that protocol therapy data that effectively treats diseases should be shared. We understand the importance of sharing this data within the community and would like to publish quality organization findings and data through our web-portal.

Changing the inherent predisposition of MSP-
particularly MSP Silver 400 can only be achieved through appropriate data interpretations, and timely and open communication.

Clinical studies in progress-
HIV studies have been ongoing in Cuba since 1998. Chagas Disease is currently being studied in Mexico. This year our MSP formulation will be used as part of the design treatment in five new clinical studies for Hepatitis C, Type II Diabetes, and AML Leukemia. MSP Research would like to encourage more development and participation in future clinical trials addressing diseases associated with harmful pathogens, including documentation of individual case study therapy treatment data.

Clinical and Pre-Clinical Studies-
Review Studies

Research Articles-
Review Articles

Ag Therapeutic Protocols- On-line Manual-
Review Protocols

Laboratory Testing: Microbiological, Bio-Analytical (product toxicity), and Quality Control-
Most of you are aware that the FDA will not allow products containing mild silver protein (MSP) to be sold with any medical claims whatsoever. Be that as it may, the undisputed effectiveness of our proprietary formulation has been validated for superior anti microbial effectiveness. Our products continually undergo analytical methods development, testing and validation for content and purity.

Microbiological Testing-
Our products have undergone comprehensive testing for anti microbial effectiveness. MSP Research- R&D utilizes the authoritative microbiological testing services of microbiologist Larry Wayne Harris to evaluate and document our product
antimicrobial effectiveness. The test results are conclusive.

Bio-Analytical (product toxicity)-
MSP Research products have undergone quality control testing for content quality and purity at the University of Florida, Allergy Research Group, Vitamin Research Products, Inc (VRP), Haeuser Labs, Gailbreth Labs and many others.

Product Toxicity Testing-
MSP Research mild silver protein proprietary formulation has been tested for toxicity. Our formulation has been shown to be non-toxic at extremely high dosages in laboratory studies with animals conducted by Dr. R.C. Renlund at the University of Toronto, Division of Comparative Medicine (DCM).

Mr. Yu Shao, PhD –
Director of Quality Control at VRP completed analytical testing on Silver 400 for Ph value, particle size, protein binding and concentration. Our certificate of analysis indicated unsurpassed content quality and purity.

Site Map I Contact Us I Terms & Conditions